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ABSTRACT
Lymphoid enhancer factor 1 (LEF-1) mediates Wnt
signaling via recruitment of b-catenin to target
genes. The LEF1 gene is aberrantly transcribed in
colon cancers because promoter 1 (P1) is a Wnt
target gene and is activated by TCF–b-catenin
complexes. A second promoter in intron 2 (P2)
produces dominant negative LEF-1 isoforms
(dnLEF-1), but P2 is silent because it is repressed
by an upstream distal repressor element. In this
study we identify Yin Yang 1 (YY1) transcription
factor as the P2-specific factor necessary for re-
pression. Site-directed mutagenesis and EMSA
were used to identify a YY1-binding site at +25 in
P2, and chromatin immunoprecipitation assays
detected YY1 binding to endogenous LEF1 P2.
Mutation of this site relieves P2 repression in tran-
sient transfections, and knockdown of endogenous
YY1 relieves repression of integrated P2 reporter
constructs and decreases the H3K9me3 epigenetic
marks. YY1 is responsible for repressor specificity
because introduction of a single YY1-binding site
into the P1 promoter makes it sensitive to the
distal repressor. We also show that induced expres-
sion of dnLEF-1 in colon cancer cells slows their
rate of proliferation. We propose that YY1 plays an
important role in preventing dnLEF-1 expression
and growth inhibition in colon cancer.
INTRODUCTION
Colorectal cancer initiation and progression frequently
develops from overactive activation of Wnt signaling
due to genetic mutation of one or more of the midstream
components. The most common mutations are found in
components of the APC (adenomatous polyposis coli)-de-
pendent destruction complex. Loss of function mutations
in APC or other components leads to stabilization and
accumulation of b-catenin in the nucleus, and this
results in constitutive and inappropriate, high levels of
transcription of target genes such as MYC, CCND1
(cyclin D1) and the Wnt-signaling transcription factor
LEF1 (1–3). About 80% of colon tumors exhibit
aberrant activation of LEF1 gene expression (4).
Aberrant expression is due to inappropriate transcription-
al activation of the LEF1 locus and unbalanced
overexpression of the Wnt- and growth-promoting
isoform of LEF1 relative to the Wnt- and growth-
suppressing isoform of LEF1.
LEF1 is a member of the LEF/TCF family of transcrip-
tion factors that mediate downstream events in the
WNT-signaling pathway. When expressed in normal
cells, the LEF1 locus produces two protein isoforms
from two diﬀerent RNA polymerase II promoters.
Promoter 1 (P1) produces a mRNA encoding a full
length LEF-1 isoform (FL-LEF1) with a b-catenin-
binding domain at the N-terminus and a DNA-binding
domain near the C-terminus (5,6). This form acts as a
Wnt- and growth-promoting form as its DNA-binding
domain recognizes Wnt response elements (WREs) in
target genes and its N-terminal domain recruits
b-catenin to those target genes for activation. Promoter
2 (P2) produces a truncated mRNA that encodes a smaller
form of LEF-1 missing the b-catenin domain. This
isoform, dominant negative LEF-1 (dnLEF-1), retains
the ability to bind to WRE but it cannot recruit
co-activator b-catenin. Dn-LEF-1 therefore suppresses
Wnt target gene activation and opposes the actions of
FL-LEF-1 and other LEF/TCF factors. In the study
here, we show that forced expression of dnLEF-1 slows
colon cancer cell growth.
In colon cancer, LEF1 is aberrantly transcribed and
transcripts come exclusively from activation of P1 since
P2 is silent. P1 is activated because the promoter is
targeted for regulation by the Wnt pathway, and this
mechanism is well deﬁned (4). P2 is actively silenced, but
the mechanism of this repression is unknown. The repres-
sion mechanism is important to deﬁne because interfer-
ence with its function might enable expression of
dnLEF-1 and therefore provide a balance to oﬀset
full-length LEF/TCF actions in cancer. We have
*To whom correspondence should be addressed. Tel: +1 949 824 2885; Fax: +1 949 824 8596; Email: mlwaterm@uci.edu
Published online 4 June 2010 Nucleic Acids Research, 2010, Vol. 38, No. 19 6375–6388
doi:10.1093/nar/gkq492
 The Author(s) 2010. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.previously shown that P1 is aberrantly activated by TCF–
b-catenin complexes that bind to WREs in the promoter.
However, we have also identiﬁed WREs in P2 (4), and we
ﬁnd that P2 can also be activated by TCF–b-catenin
complexes. Furthermore, the basal P2, which contains
three of the identiﬁed WREs, is highly active in colon
cancer cells. These data suggest that P1 and P2 have
equal potential to be activated by the Wnt pathway.
Nevertheless, in vivo chromatin immunoprecipitation
(ChIP) studies showed that P1, but not P2, is directly
occupied by TCF–b-catenin complexes in colon cancer
cell lines (4). Thus, even though P2 has at least three
WREs, these elements are not bound by TCF–b-catenin
complexes, a feature consistent with its silence in colon
cancer. A survey of chromatin acetylation surrounding
the LEF1 locus in the colon cancer genome revealed that
P1 is highly acetylated and P2 is poorly acetylated, and
interestingly, the drop in acetylation levels corresponds to
a small region between the two promoters. We identiﬁed
this region as a transcription repressor because highly
active fragments of P2 can be strongly repressed by se-
quences from this upstream region (4). Mapping experi-
ments located the repressor element to a 165-bp sequence
between  1446 and  1281 relative to the P2 transcription
start site (Figure 1). We also found that TCF–b-catenin
complexes could recognize and bind the P2 promoter only
if the repressor was deleted, suggesting that the repressor
acts to displace or disallow TCF–b-catenin complexes
from recognizing WREs (4). In contrast, the distal repres-
sor does not prevent TCF–b-catenin complexes from
binding to P1 WREs and activating transcription.
Therefore, distal repressor action does not directly target
TCF–b-catenin complexes for displacement. Here we in-
vestigate the hypothesis that the repressor indirectly inter-
feres with TCF–b-catenin action by targeting a P2-speciﬁc
protein or element.
Our investigation used site-directed mutagenesis and
molecular biology to identify Yin Yang 1 (YY1) as the
P2 factor necessary for distal repressor action on P2.
YY1 is a ubiquitously expressed, multifunctional zinc
ﬁnger transcription factor that belongs to the human
GLI-Kruppel family of nuclear proteins (7–9).
Depending on the context of cells and the environment,
YY1 can be an activator, a repressor, or an initiator of
transcription and it regulates a broad spectrum of genes.
As a repressor, YY1 is known to recruit Polycomb Group
complexes and initiate epigenetic changes in chromatin
(e.g. H3K9me3, H3K27me3) (10–12). The versatility of
YY1 is attributed to its ﬂexibility in recognizing DNA in
a variety of contexts including both distal and proximal
promoter regions (7,8). In this study we identify a
YY1-binding site in the core promoter region of LEF1
P2. We show that YY1 is necessary for the distal
element to functionally repress P2, that YY1 occupies
silent LEF1 P2 in the colon cancer genome, and that
YY1 confers distal repressor action to P1 when its
binding site is introduced into the core promoter. These
data support the model that YY1 is the distinguishing
feature of P2 that renders it susceptible to transcription
repression in colon cancer. YY1 is a regulator of cell pro-
liferation and development, and its overexpression and
activation is linked to tumorigenesis in a wide range of
human cancers, including colon cancer. Our study makes
a ﬁrst important link between YY1 actions and Wnt sig-
naling in colon cancer.
MATERIALS AND METHODS
Sulforhodamine B cell growth assay
A 10-day growth curve experiment was performed with
DLD-1 cells, which inducibly express dnLEF-1. Cells
were plated on 96-well plates (5000 cells per well) as eight
replicates for each experimental time point. Every 3 days
cellswereprovidedwithfreshmediacontainingeitherdoxy-
cycline (0.01mg/ml) or water (mock treatment control).
Cells were ﬁxed and stained according to published proto-
cols (13). Optical density readings were performed at
490nm with Spectra Max 340 from Molecular Devices
Corporation. Two independent growth curves in two dif-
ferentDLD-1 dnLEF-1stablecell lineswere carriedoutfor
10 days, and the SD was generated from eight replicates.
Reporter plasmid constructs
Fusion of the 165-nt repressor element to diﬀerent se-
quences of P2 plasmids [ 27/+30,  27/+60,  77/+60
and  177/+6, previously described in Li et al. (4)] was
achieved by PCR ampliﬁcation of repressor sequences
and ligation of the repressor fragment in front of the fol-
lowing P2 pGL2E reporters (R 27/+30, R 27/+60,
23
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Figure 1. Two promoters in the LEF1 locus. The LEF1 locus contains two RNA polymerase II promoters. One promoter (P1) produces an mRNA
that encodes full-length LEF-1 protein. A second promoter in intron 2 (P2) produces an mRNA that encodes the shorter, dominant negative LEF-1
isoform. Both promoters contain bona ﬁde WREs (blue WREs) that mediate activation by TCF–b-catenin complexes. P1 and P2 expression patterns
are aberrant in colon cancer cells. P1 is aberrantly activated by TCF–b-catenin, whereas P2 is silenced by a distal repressor located between –1446
and –1281nt upstream relative to the P2 transcription start site (red circle). The repressor targets a unique feature of basal P2 as P1 is not silenced by
the repressor.
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promoter constructs ( 24mt, +10mt, +14mt, +19mt,
+25mt, YY1mt) were generated by site-directed mutagen-
esis PCR methods (Strategene). Parallel mutations were
introduced in two reporter plasmids, one without the re-
pressor sequence and one with the repressor sequence
( 27/+30 pGL2E and R 27/+30 pGL2E). The YY1
mutation was also generated in the  1446/+60 pGL2B
P2 construct. The plasmid containing the repressor
region upstream of LEF1 P1 (R P1) was previously
described in Li et al. (4). To introduce a YY1 site in the
P1 and R–P1 plasmids, a 3-nt mutation was introduced by
site-directed mutagenesis. All plasmid constructs were
veriﬁed by restriction enzyme digestion and DNA
sequencing. A bacterial expression vector of His-tagged
YY1 (in pGEX-4T-2) was a generous gift from G. Sui
(Wake Forest University, Winston-Salem, NC, USA.).
Transient transfection assay
Colo320HSR cells (0.4 10
6), DLD-1 cells (0.4 10
6),
SW480 cells (0.4 10
6) were all transfected with 0.5mg
of reporter plasmid and 0.1mg of cytomegalovirus
(CMV)- b-galactosidase plasmid using FuGENE 6
reagent according to the manufacture’s protocol (Roche
Molecular Biochemicals). Cells were harvested at 18–20h
post-transfection and assayed for luciferase activity.
Luciferase activity values were normalized using
b-galactosidase activity values. Fold activation was
calculated as a ratio of luciferase levels from each
reporter construct. In all cases, experiments were per-
formed with duplicate samples, and at least three or
more independent experiments were performed.
Electrophoretic mobility shift assay
Electrophoretic mobility shift assay (EMSA) reactions
were carried out with 1 or 2pmol ( 200cps) of oligo-
nucleotide (see sequence listed in Figure 4A) and
0.05–0.3mg puriﬁed YY1 in a ﬁnal reaction volume of
25ml containing 15mM HEPES (pH 7.9), 0.1% NP-40,
10% glycerol, 30mM KCl, 5mM MgCl2, 0.1mM ZnCl2,
0.5mg of poly(dI-dC), 18.8mg BSA and 5mM
dithiothreitol. YY1 antibody (1–4mg; Santa Cruz
sc-7341x) or Rat IgG (Santa Cruz, negative control) was
added to 0.15mg of YY1 protein in gel shift buﬀer (above)
for 1h at 4 C, followed by addition of probe.
Recombinant His-tagged YY1 protein was expressed in
Rosetta cells, using induction with 0.15M IPTG for
3.5h at 37 C. Sonicated bacterial lysates were applied to
a nickel His-trap column (Amersham) and protein was
eluted according to the manufacturer’s protocol. The fol-
lowing wild-type and mutated oligonucleotides were
annealed with complementary strands: wild-type 50-AAA
GCATCCAGATGGAGGCCTCTAC-30, mutant 50-AAA
GCATCCAGCGTGAGGCCTCTAC-30.
ChIP
Cross-linking and lysate preparation was performed ac-
cording to the Upstate Biotechnology protocol with modi-
ﬁcations. Eight plates of 3 10
6 cells (Colo320 HSR cells,
Colo320  1446/+60 shScr and  1446/+60 shYY1) were
cross-linked with 1% formaldehyde for 10min at room
temperature. Cross-linking was stopped with the
addition of 125mM glycine and cold PBS for 10min.
Cross-linked cells were centrifuged at 1200r.p.m. for
10min at 4 C and washed with 1X PBS and subsequently
resuspended in sodium dodecyl sulfate lysis buﬀer
(Upstate) with protease inhibitors and 1mM
phenylmethylsulfonyl ﬂuoride and incubated on ice for
10min. Crossed-linked DNA was sheared by sonication
to an average size of between 350 and 800nt. YY1
antibody (Sc-7341x) was obtained from Santa Cruz
Biotechnology, CA, USA. Antibody against pan-speciﬁc
Histone (MAB052, detects Histone H1 and nucleosomal
H2A, H2B, H3 and H4) was obtained from Chemicon
International. Histone H3K9me3 antibody (ab8898) and
Histone H3K27me3 antibody (ab6002) were obtained
from Abcam. Magnetic beads carrying mouse and rabbit
secondary antibodies were purchased from Dynal
(Invitrogen, CA, USA). Primary antibodies (10mg
anti-YY1, 5mg anti-Histone, 10mg anti-H3K9me3, 10mg
anti-H3K27me3 or 10mg IgG) were immobilized on
magnetic beads in PBS/BSA overnight at 4 C.
Chromatin ( 0.5mg) was immunoprecipitated with
100ml beads/antibody in 1% Triton-X, 0.1% DOC and
protease inhibitor at 4 C overnight. Immunoprecipitates
were washed eight times in RIPA buﬀer and eluted from
the beads with elution buﬀer (10mM Tris, pH8, 1mM
EDTA, 1% SDS) at 65 C for 15min and treated with
283mM NaCl for reverse cross-link. DNA was treated
with proteinase K and subsequently phenol-chloroform
extracted and ethanol precipitated. The primer pairs
used for the PCR survey of YY1 occupancy of P2 were:
50-CTGGTTTGCTGCTAAGCTATTTAAGAGAATA-30
and 50-TGTTCTCGGGATGGGTGGAGAAAG-30. Prim-
ers for ZNF609:5 0-CTCTCTGCTCCTCCTGTTCG-30
and 50-CAATATCCACTTTACCAGAGT-30.
Primers for LEF1 intron3 ( 40.5kb downstream of P2):
50-TGCTCCACAGCATATGGCAGAAGTG-30 and
50-GGCTCATGGGGCCATGTTTCCT-30.
Band intensities of the PCR products are presented as a
ratio over the intensity obtained from total input supplied
to each immunoprecipitation reaction (+Ab/Input).
The ChIP analysis of methylated histones was
quantiﬁed by real-time PCR (qPCR). Enrichment was
calculated as percentage of input DNA, and IgG
was used as negative control and subtracted from enrich-
ment values. Each qPCR point was performed in tripli-
cates and the average was calculated from two
independent ChIP analyses. qPCR primers as follows:
P2 Integrated: 50-AAACAAATCTTTTATGTAGGGT
CTGA-30 and 50-CTTTATGTTTTTGGCGTCTTCCA-30.
Endogenous P2 ( 108 to+82): 50-AAACAAATCTTTT
ATGTAGGGTCTGA-30 and 50-GCATCATTATGTAC
CCGGAATAAC-30
GAPDH: 50-TACTAGCGGTTTTACGGGCG-30 and
50-TCGAACAGGAGGAGCAGAGAGCGA-30.
Cell culture
Colo320 HSR, DLD-1 and SW480 colon cancer cells were
cultured in RPMI 1640 with 10% fetal bovine serum and
Nucleic Acids Research, 2010,Vol.38, No. 19 63772mML-glutamine (RPMI complete). Colo320  1446/+60
and  816/+60 stable cells were cultured in RPMI
complete media supplemented with 200mg/ml G418 (4).
Colo320  1446/+60 shYY1,  1446/+60 shScr,
 816/+60 shYY1 and  816/+60 shScr cells were
cultured in RPMI complete media supplemented with
200ml/mg G418 (A.G. Scientiﬁc), 10mg/ml blasticidin
(InvivoGen), and 5mg/ml puromycin (InvivoGen).
DLD-1 TR7 cells (2 10
5, DLD-1 colon cancer cells ex-
pressing Tet repressor; generous gift from M. van de
Wetering and H. Clevers) were transfected with a vector
for Tet inducible dnLEF-1N (2mg) by Eﬀectene transfec-
tion reagent (QIAGEN). Stably transfected cells were
selected in complete RPMI media containing 500mg/ml
Zeocin (InvivoGen) and 10mg/ml Blasticidin
(InvivoGen) and those cells that were resistant to Zeocin
and Blasticidin were isolated as single colonies. These
clonal cells were expanded into individual cell lines and
screened for induction of dnLEF-1N protein expression
by western blot analysis.
shRNA inducible cell lines
Colo320  1446/+60 and  816/+60 stable cell lines
were used as parental cell lines to establish stable cell
lines that constitutively express the Tetracycline repressor
(TR) and inducibly express shRNA. We ﬁrst created a
stable cell line that expresses the TR by transiently trans-
fecting pcDNA6/TR (Invitrogen). Colo320  1446/+60
and  816/+60 cells (2 10
6) were transfected with
pcDNA6/TR (3mg) by use of eﬀectene transfection
reagent (QIAGEN). Stably transfected cells were selected
in media containing 200ml/ml G418 and 10mg/ml
blasticidin and those cells that were resistant to G418
and blasticidin were pooled 3 weeks after the initial trans-
fection. These new cell lines ( 1446/+60TR and
 816/+60TR) were used to create a second cell line that
expresses shRNA from pSUPERIOR.puro vector
(OligoEngine, Inc.). The shRNA sequence targeting
human YY1 has been previously designed and validated
(14). The template for shRNA expression was obtained by
annealing oligonucleotides (50-GATCCCCGGCAGAAT
TTGCTAGAATGTTCAAGAGACATTCTAGCAAAT
TCTGCCTTTTTA-30 and 50-AGCTTAAAAAGGCAG
AATTTGCTAGAATGTCTCTTGAACATTCTAGCA
AATTCTGCCGGG-30). Annealed oligonucleotides
were designed to carry BglII and HindIII compatible over-
hangs enabling them to be ligated into the BglII and
HindIII linearized vector pSUPERIOR.puro. A mamma-
lian scrambled oligonucleotide (MAMM-2; OligoEngine)
was ligated into the pSUPERIOR.puro vector as a
shRNA negative control (shScr). Colo320  1446/+60TR
and  816/+60TR were transfected with each of the
shRNA (shYY1 and shScr) using Eﬀectene following the
manufacturer’s protocol. Stable cell lines were selected
with 200ml/mg G418, 10mg/ml blasticidin and 5mg/ml
puromycin. Stable cells that were resistant to G418,
blasticidin and puromycin were pooled 3 weeks after
transfection.
Western blot analysis
About 25mg of DLD-1 Tet_induced dnLEF-1N lysates
(dnLEF1A and dnLEF1 B cells, Figure 2) were
analyzed by western blot analysis. Anti-ﬂag (F-3165
Sigma) and anti-LEF1 (#2286 Cell Signaling) antibodies
were used to detect LEF-1 expression and anti-Lamin A/C
(#2032 Cell Signaling) was used as loading control.
Recombinant His-tagged YY1 protein (0.3mg) was
also analyzed by western blot (Figure 4A) using an
anti-YY1 monoclonal antibody (Santa Cruz sc-7341x)
Cell lysates of 1.5 10
5 Colo320 stable cells (–1446shScr,
 1446shYY1,  816shScr,  816shYY1) treated with
doxycycline (1mg/ml) were analyzed for expression of
YY1 by western blotting (Figure5) with a polyclonal
YY1 antibody (#2185 Cell Signaling) and secondary
anti-rabbit IgG conjugated to horseradish peroxidase
(Santa Cruz Biotechnology). Monoclonal b-tubulin
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Figure 2. Overexpression of dnLEF-1 slows down DLD-1 colon cancer
cell growth. The eﬀect of doxycycline-induced expression of dnLEF-1
on DLD-1 colon cancer cell growth was monitored over a 10-day
period in two diﬀerent clonal stable cells lines [dnLEF1(1) and
dnLEF1(2)]. Quantitation of cell number with or without doxycycline
(0.01mg/ml) was performed using a sulforhodamine B cell proliferation
assay (colorimetric-based growth curve). Diﬀerences in the rate of cell
growth appeared after 4 days after which the dnLEF-1 expressing cells
grew at a signiﬁcantly reduced rate. A representative graph is shown
from two independent trials. Error bars depict SDs of the results
obtained with eight replicates from one trial. The western blots above
the cell growth assay show the induced levels of expression of
ﬂag-tagged dnLEF-1 protein after 24h of doxycycline treatment.
Endogenous LEF-1 is also detected with LEF1 antibody (FL-LEF-1).
Lamin antisera is used for a loading control.
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control. All blots were developed with SuperSignal West
Dura Luminol/Enhancer reagent (Thermo Scientiﬁc).
Luciferase assay for stable cells
All four Colo320 stable cells ( 1446/+60 shScr,
 1446/+60 ShYY1,  816/+60 shScr,  816/+60 shYY1)
were seeded in six-well plates (150000 cells) 24h prior to
doxycycline treatment. Doxycycline (1mg/ml) was added
to the cultures to induce either shRNA YY1 or shScr and
cells were harvested 0, 24, 36, 48 and 60h after doxycyc-
line treatment for luciferase and b-galactosidase assays.
The luciferase activities were normalized to the
b-galactosidase activities.
RESULTS
Expression of dnLEF1 attenuates colon cancer cell growth
Overexpression of dominant negative forms of TCFs can
halt the growth of colon cancer cells via a strong stall in
cell-cycle progression (15,16). If transcription silencing of
LEF1 P2 was disrupted and dnLEF-1 expressed, then
dnLEF-1 might have a similar eﬀect on colon cancer
cells. We therefore investigated whether induced expres-
sion of dnLEF-1 could aﬀect colon cancer cell growth. To
test this we developed stable DLD-1 colon cancer cell lines
with doxycycline inducible expression of ﬂag-tagged
dnLEF-1 protein. Using a colorimetric-based growth
curve assay, we monitored cell growth over a 10-day
period in the absence or presence of induced dnLEF-1
expression in multiple, independent clonal stable cell
lines [two cell lines are shown in Figure 2 as dnLEF1 (1)
and dnLEF1 (2)]. Western analysis conﬁrmed the expres-
sion of dnLEF-1 within 24h of doxycycline induction
(Figure 2). Diﬀerences in the rate of cell growth
appeared after 4 days, which was also when the cultures
approached conﬂuency. At the point of conﬂuence (Day
5), the dnLEF-1 expressing cells continued to grow but at
a signiﬁcantly reduced rate (50%) compared with the
mock-treated cells (Figure 2). This reduction in cell
growth occurred regardless of dnLEF-1 induction levels,
which varied between the two cell lines. These data suggest
that repression of endogenous dnLEF-1 expression
enables faster rates of colon cancer cell proliferation.
The P2 core promoter is a target of repression
To examine the mechanism of P2 repression by the
upstream repressor region, we investigated whether re-
pression is position dependent and whether intervening
sequences between  1281 and the transcription start site
are important. Placement of the 165-bp repressor element
in diﬀerent positions upstream of P2 in a luciferase
reporter plasmid and transfection of these reporter
plasmids into Colo320 colon cancer cells showed that re-
pression was possible from any position upstream of P2
(Figure 3A). Deletion of sequences downstream of the
transcription start site from+60 to+30 reduced repression
from 8.9- to 2.7-fold. Overall however, the deletion study
showed that the repressor element speciﬁcally targets core
promoter sequences between  27 and+30.
The target of the repressor is an element at+25 relative
to the start site of P2 transcription
We previously reported that distal repressor action is
speciﬁc to P2 and has no eﬀect on P1 either upstream or
downstream (4). These observations imply that diﬀerences
in the promoters make them sensitive or insensitive to re-
pressor action. Given that the repressor acts on core P2
( 27/+30), we hypothesized that a factor(s) binding to
sequences within this 57-nt region was important for com-
munication with the distal repressor. To deﬁne the
sequence elements in core P2 that are targeted by the re-
pressor, multiple mutations were introduced between
 27 and +30 by site-directed mutagenesis. We have pre-
viously shown that mutating the initiator-like element (–
17) and the WRE that overlaps the transcription start site
(+1) results in an inactive core P2 [(4); bold text Figure 3B
P2 wild-type]. Therefore only nucleotides upstream and
downstream of these essential elements were mutated.
Each mutation was introduced into two reporter
plasmids that diﬀered by the presence or absence of the
repressor element ( 27/+30 pGL2 and R 27/+30 pGL2).
P2 sequences and the mutations within  27 to +30 are
shown in Figure 3B. These mutated reporter plasmids
were then analyzed for promoter activity and repression
by transient transfection in Colo320 colon cancer cells
(Figure 3C). Overall, mutations in the core promoter
had a negative eﬀect on core P2 activity. This is
expected since many known Polymerase II preinitiation
components require interactions with key positions near
transcription start sites. Mutation of+10 to+12 especially
had a negative eﬀect on P2 activity since the mutations are
close to the initiator element. However, despite these
eﬀects, repression was still evident for most constructs as
promoter activity was reduced to similar or lower levels
compared to the wild-type repressed promoter (Figure 3C;
dotted line, R 27/+30). The one exception was a
mutation that altered 4nt: +25 to +28 (TGGA to
GTTC). Mutagenesis of these nucleotides had only
modest eﬀects on core P2 activity, yet almost completely
prevented repression (R+25mt, Figure 3C). We conclude
that a sequence element at +25 is recognized by a key
factor for repression.
Inspection of the +25 sequence element revealed a
match to the consensus binding site for the ubiquitously
expressed YY1 transcription factor (CAGATGGAG).
This factor is known to mediate both transcription acti-
vation or transcription repression (7,8). To determine if
the putative YY1 consensus sequence is important for
P2 repression, we introduced a more precise mutation to
destroy the core YY1-binding site at +24 and +25
(YY1mt, Figure 3D). Wild-type P2 (P2 WT), the+25mt,
and the new YY1mt reporter plasmids (with or without
the repressor element) were analyzed for promoter activity
and repression by transient transfection in three colon
cancer cell lines (Colo320, DLD-1 and SW480,
Figure 3D). Consistent with the previous result,
mutating the core promoter region had a negative eﬀect
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However, mutating the putative YY1-binding site resulted
in either partial (+25mt) or complete (YY1mt) relief of
repression when comparing the mutants with the repressor
to the mutants without the repressor (compare YY1mt
with R-YY1mt in Colo320, gray bars, Figure 3D).
Although we observed the greatest relief of repression in
Colo320 cells, the promoter activity proﬁles for all three
cell lines were similar.
We also introduced the YY1 mutation (YY1 mt) in the
more physiologically relevant  1446/+60 reporter plasmid
where the repressor element is at the native location and
analyzed promoter activity by transient transfection in
colon cancer cell lines (Figure 3E). For all three cell
lines, introduction of the 2-nt mutation at the YY1 con-
sensus sequence resulted in relief of P2 repression (3- to
7-fold). We conclude that a YY1 element between+21 and
+28 is necessary for full repressor function.
YY1 binds to the+25 region of P2 in vitro and in vivo
To determine if YY1 could bind to the +25 element,
EMSA was performed with partially puriﬁed, recombin-
ant His-tagged YY1 protein and radiolabeled wild-type
and mutant probes encoding (+13 to +37) of P2
(Figure 4A). Puriﬁed, intact and pure His-tagged YY1
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Figure 3. An element in core promoter P2 is necessary for repression. (A) The 165-nt distal repressor (red box) was fused to P2 at diﬀerent upstream
positions (from –177 to –27 relative to the start site of transcription). Promoter activities were analyzed by luciferase reporter assays in Colo320 colon
cancer cells. All promoter fragments were sensitive to repression, therefore, the repressor speciﬁcally targets core P2 sequences between –27 and+30.
Data are derived from duplicate samples, and the results shown represent one of four replicate experiments. Fold activation was calculated as a ratio
of luciferase levels from each reporter construct relative to the promoterless reporter vector. Error bars represent the spread between duplicate
samples. (B) Multiple mutations of core P2 were generated by site-directed mutagenesis. P2 sequences from –27 to +30 are shown. Each mutation
was introduced into pairs of luciferase reporter plasmids that diﬀered only by the presence of the distal repressor element at –27 (pGL2E R–27/+30
and pGL2E –27/+30). Black bolded nucleotides show the essential initiator sequence (–17) and the transcription start site (+1). Green bolded
nucleotides show the ﬁve diﬀerent mutated sequences. (C) Luciferase assays of the mutated P2 reporter plasmids are shown. P2 reporter plasmids
were transiently transfected into Colo320 cells. Mutations of core promoter sequences reduced P2 activity in all cases (gray bars), whereas only the
mutation at +25 relieved repression by the distal repressor (black bars). Luciferase activity is reported as activation over that for a promoterless
reporter vector. Data are derived from duplicate samples, and the results shown represent one of three replicate experiments. Error bars represent the
spread between duplicate samples. (D) A mutation to destroy the YY1-binding site at +24 and +25 (AT to GG, in red) was introduced by
site-directed mutagenesis. The mutation was introduced in luciferase reporter plasmid pGL2E R 27/+30 and pGL2E  27/+30 (P2 WT and R P2
WT respectively). Wild-type P2 and mutated P2 reporter plasmids were transiently transfected into three diﬀerent colon cancer cell lines (Colo320,
DLD-1 and SW480). Data shown are from a representative experiment out of three trials; error bars represent the spread of duplicate samples. The
mutation at the YY1-binding site resulted in partial relief of repression in all three cell lines. (E) A YY1-binding site mutation was also introduced in
the more physiologically relevant reporter plasmid pGL2B  1446/+60. Both wild-type  1446/+60 P2 and  1446/+60 YY1mt reporter plasmids were
transiently transfected into three diﬀerent colon cancer cell lines (Colo320, DLD-1, and SW480). Data are derived from three replicate experiments
and error bars represent SDs of the data. For all three cell lines, introduction of the YY1-binding site mutation showed relief of P2 repression.
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Figure 3. Continued.
Nucleic Acids Research, 2010,Vol.38, No. 19 6381protein is shown in Coomassie stained SDS–PAGE gel as
well as in western blot analysis probed with anti-YY1
antibody (Figure 4A). Results from the EMSA assay
showed that YY1 binds to the +25 wild-type sequence
but not to the mutant probe. Addition of YY1 monoclo-
nal antibody to the EMSA-binding reaction blocked
binding, showing that it is YY1 protein that is speciﬁcally
binding to the +25 region and not an irrelevant protein
from the bacterial extracts (Figure 4A, far right). A faster
migrating form is not aﬀected by YY1 monoclonal
antibody.
We next performed ChIP assays to assess whether en-
dogenous YY1 binds to the +25 region of endogenous
LEF1 P2. ChIP assays were performed using monoclonal
YY1 antibody to pull down cross-linked YY1/DNA
complexes from Colo320 colon cancer cells. Occupation
of YY1 over the core P2 promoter region was detected
with primers that amplify the genomic region from  188
to+144 relative to P2. A primer set that detects intron3 of
the LEF1 gene ( 40.5-kb downstream of P2) and a set
that detects an unrelated region of the genome
(ZNF609) were used as negative controls for the assay.
Immunoprecipitation data is represented as the percent
of PCR product ampliﬁed from the immunoprecipitates
over the total amount of product ampliﬁed from the
input (input set at 100). A pan-speciﬁc histone antibody
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Figure 4. YY1 binds to the+25 region of P2 in vitro and in vivo. (A) EMSA was performed with a
32P-labeled P2 probe containing the putative YY1
wild-type sequence (-CAGATGGAG-) or a mutated sequence (-CAGCGTGAG-) and puriﬁed recombinant human His-tagged YY1 protein. Puriﬁed
His-tagged YY1 is shown in both Coomassie stained SDS–PAGE gel and YY1 probed western blot. Protein was added in increasing amounts (0.05,
0.1, 0.15 and 0.3mg) (left EMSA). To conﬁrm binding speciﬁcity, 1, 2 or 4mg YY1 monoclonal antibody was included in the EMSA assay with
0.15mg puriﬁed YY1 protein and
32P-labeled P2 probe (right EMSA). YY1 antibody blocked formation of the larger complex, but not the faster
migrating complex. Arrows point to the YY1 bound probe. (B) ChIP assay was performed with Colo320 cells lysates. Chromatin from
formaldehyde-crosslinked Colo320 cells was immunoprecipitated with monoclonal YY1 and pan-speciﬁc Histone antibodies. ChIP immunopre-
cipitates were analyzed by PCR primers that detect the core P2 region ( 188 to +144), intron3 of the LEF1 gene, and an unrelated region of
the genome (ZNF609). Data are derived from two to three independent experiments and error bars represent standard deviations. The diﬀerence
between YY1 and IgG occupancy was signiﬁcant for the core P2 region (P<0.05) but insigniﬁcant for intron3 or ZNF609 (Student’s t test).
Representative gels for each primer set are shown.
6382 Nucleic Acids Research, 2010,Vol.38, No. 19that detects all four core, nucleosomal histones was
used as a positive control for the cross-linking and
immunoprecipitation, and IgG serum was used as a
negative and background control. We observed YY1 spe-
ciﬁcally binding to the core P2 promoter as YY1 antibody
was nearly as eﬀective as histone antibody in the
immunoprecipitation of core P2 sequences (Figure 4B;
50 versus 60%). Based on these results, we conclude
that the YY1 transcription factor speciﬁcally binds to
the core P2 promoter. Since mutation of the
YY1-binding site at+25 interferes with promoter repres-
sion and YY1 binds to this sequence both in vitro and
in vivo, these correlative data strongly suggest that YY1
is the functional protein target of the repressor. To more
directly test for the importance of YY1 in P2 repression,
we carried out two functional studies: a knockdown of
endogenous YY1 to test for eﬀects on P2 repression and
epigenetic modiﬁcations to chromatin, and introduction
of the YY1-binding site into a heterologous promoter to
test for the ability of this site to confer repressor
sensitivity.
YY1 is necessary for P2 repression
To knockdown endogenous YY1 in colon cancer cells we
created an inducible shRNA YY1 system in two Colo320
colon cancer cell lines which have P2 luciferase reporter
plasmids integrated into the genome [ 816/+60 and
 1446/+60, (4)]. Using luciferase as a readout of the
integrated reporters, we previously showed that in the
context of the colon cancer genome and authentic chro-
matin structures, the upstream repressor acts on P2 to
repress transcription and prevent TCF–b-catenin
complexes from occupying their cognate WREs (4). A
co-integrated plasmid with the b-galactosidase reporter
gene driven by the CMV promoter was used as a normal-
ization control to compare luciferase activities between the
two cell lines. Thus, normalized luciferase levels in the
 816/+60 cell line is high because the integrated P2
reporter is missing the repressor element (Figure 5B). In
contrast, normalized luciferase activities in the  1446/+60
reporter line are lower because the repressor is present
(Figure 5A). If YY1 is an essential core P2 factor for re-
pressor action, then knockdown of endogenous YY1
should relieve repression of the integrated  1446/+60
P2-luciferase reporter, but should have no eﬀect on the
 816/+60 P2 reporter. To test this hypothesis we estab-
lished a TR system for inducible shRNA YY1 (shYY1)
knockdown in the  816, and  1446 reporter lines
(’Materials and methods’ section). We also made comple-
mentary stable cell lines that have an inducible scrambled
shRNA (shScr) as a negative control (Figure 5). In
addition, the co-integrated b-galactosidase reporter
plasmid was used as an internal negative control for
YY1 knockdown. Doxycycline was added to the cultures
of these newly derived sub-lines to induce either shRNA
YY1 or scrambled sequences and cells were harvested 0,
24, 36, 48 and 60h after treatment. Western analysis of the
 1446/+60 inducible shYY1 cells showed signiﬁcant re-
duction of YY1 protein expression by 36h, whereas the
scrambled shScr negative control did not aﬀect YY1 even
after 60h of doxycycline treatment. For the  816/+60
shYY1 inducible cells, we observed leaky expression of
the YY1-speciﬁc shRNA, as YY1 protein levels were
partly reduced at 0h even before doxycycline treatment.
However, we observed further reduction of YY1 protein
during the 60h doxycycline time course. Since each of the
stable cell lines have the luciferase and b-galactosidase
reporter plasmids integrated in the cellular genome, we
assayed extracts from the doxycycline-treated cells for
both luciferase and b-galactosidase activities. Luciferase
assays showed that knockdown of endogenous YY1 in
the stable cell line with the P2 repressor ( 1446/+60) led
to partial up-regulation of P2 activity. No change in P2
activity was observed with induction of scrambled shRNA
(shScr) demonstrating that expression changes were
YY1-speciﬁc. We did not observe signiﬁcant up-regulation
or down-regulation of the P2 reporter without the repres-
sor ( 816/+60) when either YY1 or scrambled shRNAs
were induced. Taken together, results from the
knockdown studies show that YY1 is necessary for P2
repression.
To elucidate the mechanism of YY1-mediated repres-
sion, we investigated the pattern of chromatin modiﬁca-
tions associated with gene inactivity and YY1 repression
(10–12,17). Histone H3K9me3 and H3K27me3 are
commonly linked to Polycomb group activities (10–12)
and we tested for the presence of these marks on the P2
promoter in the presence and absence of YY1. We per-
formed ChIP analysis with lysates from the previously
described  1446/+60 shYY1 and  1446 shScr cell lines
with or without doxycycline induction of YY1
knockdown. We used two sets of primers to detect the
repressive marks on P2: a set that detects repressive
marks on only the P2 integrated reporter plasmid
(Figure 5C, P2Integrated) and another set that detects
repressive marks on the endogenous LEF1 P2 locus
(Figure 5C, P2 Endogenous). A GAPDH primer set was
used as the negative control. In the cell line containing
YY1 protein (–1446 shScr), we observed enrichment of
the repressive histone-tail mark H3K9me3 on both the
integrated and endogenous P2 compared to the GAPDH
promoter. However, H3K9me3 was much higher in the
integrated P2 compared to the endogenous locus. We
did not detect signiﬁcant enrichment of histone
H3K27me3 marks on P2. In the cell line with reduced
YY1 protein (–1446 shYY1), the high levels of
H3K9me3 were drastically reduced on the integrated P2
locus. There was little-to-no change of H3K9me3 on the
endogenous locus. Therefore, from this study we detected
diﬀerential levels of histone methylation between the
LEF1 integrated P2 and endogenous locus, and found
that YY1 is necessary for methylation of integrated P2,
but not for endogenous P2.
YY1 confers repressor regulation to LEF1 P1
If YY1 is the essential core P2 factor that confers suscep-
tibility to the upstream repressor, then introduction of a
YY1-binding site into a heterologous promoter should
confer a similar susceptibility. To test this we introduced
YY1-binding sequences into Promoter 1 (P1) of the LEF1
Nucleic Acids Research, 2010,Vol.38, No. 19 6383gene. We have previously shown that LEF1 P1 is highly
active in colon cancer and is regulated by TCF–b-catenin
complexes. We have also shown that LEF1 P1 is insensi-
tive to the repressor element as its placement upstream of
P1 has no eﬀect on transcription (4). Like P2, the P1
promoter is a TATA-less RNA polymerase II promoter
with multiple WREs that activate transcription. However
unlike P2, P1 is highly GC-rich, its essential core promoter
sequences are diﬀerent, and importantly, there are no
YY1-binding sites in the promoter (Figure 6A).
Therefore, we used this promoter to test whether introduc-
tion of a single YY1-binding site is suﬃcient to make P1
sensitive to the repressor region. Site-directed mutagenesis
was used to alter the nucleotide sequence at three positions
to create a YY1-binding site at+25 within core P1. These
changes were introduced both in the presence and absence
of the upstream repressor element (Figure 6B, R–P1 YY1
and P1 YY1 respectively), and promoter activities were
assessed by transient transfection into three diﬀerent
colon cancer cell lines (Colo320 cells, DLD-1 and
SW480). Similar to our previously reported ﬁndings,
wild-type P1 activity was not aﬀected by the repressor
(Figure 6B, compare P1 to R–P1) and introduction of a
YY1 site had a minimal eﬀect (Figure 6B, compare P1
to P1 YY1). Most importantly however, the modiﬁed
P1 promoter was now repressor sensitive. We observed
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Figure 5. YY1 knockdown relieves P2 repression. Inducible shRNA YY1 (shYY1) and shRNA Scrambled (shScr) stable cell lines were derived from
(A) Colo320  1446/+60 and (B)  816/+60 luciferase reporter lines (‘Materials and Methods’ section). Knockdown was induced with 1mg/ml of
doxycycline and cells were harvested 0, 24, 36, 48 and 60h after treatment and processed for western blot analysis and luciferase assays. Doxycycline
induction of YY1-speciﬁc shRNA leads to knockdown of YY1 protein (western insets; –1446 shYY1 and –816 shYY1), whereas induction of a
scrambled, negative control shRNA has no eﬀect ( 1446/+60 shScr and  816/+60 shScr). Anti b-tubulin antibody was used to control for loading in
the western blot analysis. All four cell lines carry LEF1 P2 luciferase and CMV-b-galactosidase reporter plasmids integrated in the cellular genome,
therefore, we assayed extracts from the doxycycline-treated cells for both luciferase and b-galactosidase activities. b-galactosidase activity was used to
normalize luciferase light units. The data are represented as ratios of luciferase light units to b-galactosidase units, and the error bars reﬂect standard
deviation of the data from three independent assays. (C) ChIP assay was performed with  1446/+60 reporter integrated Colo320 stable cells with
induction of either shScr or shYY1 plasmid to reduce YY1 protein levels. Chromatin from formaldehye-crosslinked cells (either shScr or shYY1) was
immunoprecipitated with pan-speciﬁc Histone, polyclonal H3K9me3, monoclonal H3K27me3 and IgG antibodies. ChIP immunoprecipitates were
analyzed by qPCR primers that detect integrated P2 ( 108 to+60), endogenous P2 ( 108 to+82), and primer set that detects the promoter of the
GAPDH gene. Data are derived from two independent ChIP experiments and qPCR was performed in triplicate.
6384 Nucleic Acids Research, 2010,Vol.38, No. 192.5- to 5-fold repression of P1 in the presence of the re-
pressor depending on the cell line (Figure 6B, R–P1 YY1),
a level similar to the 3-fold repression of core P2 shown in
Figure 3A. These results suggest that the repressor is spe-
ciﬁcally interacting with YY1 to repress core promoter
activities, and they show that YY1 sites are suﬃcient to
confer repressor susceptibility. Based on the ﬁndings from
these two functional studies, we conclude that the
upstream repressor requires YY1 to actively repress P2
and that YY1 is the unique, distinguishing feature
between P1 and P2.
DISCUSSION
Wnt signaling is important for regulating self-renewal,
survival, proliferation and developmental cell fates
and LEF-1 is one of four LEF/TCFs that can mediate
these regulatory actions. Because both P1 (FL-LEF-1)
and P2 (dnLEF-1) have bona ﬁde WREs in their
promoters, it is tempting to speculate that Wnts
coordinately regulate transcription of both LEF1 pro-
moters and in so doing establish a system of positive
and negative regulatory feedback. Indeed both LEF1
mRNA isoforms are dynamically expressed during
Wnt-dependent lymphocyte diﬀerentiation and peripheral
activation of CD8+ T lymphocytes (18). Wnt signaling
is also important for proliferation and diﬀerentiation of
epithelial cells in crypts of the intestine, but LEF1 is not
normally expressed in this tissue. Instead, LEF1 expres-
sion is turned on during intestinal carcinogenesis. LEF1
mRNA appears at the adenomatous stage and stays on
through the carcinoma and metastatic stages (4,19–21).
We have previously shown that this expression depends
entirely on the Wnt pathway and activated TCF–b-catenin
complexes binding to WREs in the LEF1 P1 promoter
(4,19). The study here explored our previous ﬁnding that
LEF1 P2 is not activated in these cancers because it is
transcriptionally repressed and its promoter WREs are
unoccupied (4). The biological outcome of diﬀerential
promoter activity is an unbalanced pattern of LEF1 tran-
scription where only the Wnt-promoting FL-LEF-1 form
is expressed and the Wnt-opposing dnLEF-1 form is
not expressed. Not only is it important to understand
the mechanisms that set up this pattern of expression,
but it may be important for understanding expression
changes observed for other LEF/TCF family members,
and other genes with multiple, diﬀerentially expressed
promoters.
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Figure 6. Introduction of a YY1-binding site confers repressor sensitivity to Promoter 1. (A) Wild-type P1 sequences ( 27/+30) and a mutant P1
with an introduced YY1-binding site (boxed in green) are shown. For comparison, wild-type sequence of core P2 with its native YY1-binding site is
shown. Site-directed mutagenesis was used to introduce the YY1-binding site into core P1 between+19 and+22 of two luciferase reporter plasmids
that diﬀered only by the presence and absence of the distal repressor element (P1 YY1 and R–P1 YY1). (B) Transient transfections of the indicated
reporter plasmids were performed in Colo320, DLD-1 and SW480 colon cancer cell lines. The distal repressor element is indicated by a red box, the
introduced YY1-binding site by a green oval and the core P1 promoter by a grey box. Luciferase activity is reported as fold activation over that for a
promoterless reporter vector. Data are derived from duplicate samples, and the results shown are a representative of at least three experiments. Error
bars represent the spread of duplicate samples.
Nucleic Acids Research, 2010,Vol.38, No. 19 6385In normal intestinal cells, two predominant TCF tran-
scription factors are expressed: full-length TCF-4
(FL-TCF-4) and dominant negative TCF-1 (dnTCF1)
(1,20,22,23). Just as we observe for LEF-1 expression in
developing lymphocytes, expression of the two forms of
TCFs that oppose each other also provides a balance
between the activities of Wnt-promoting and
Wnt-suppressing forms. Interestingly, we have discovered
that the growth suppressing form of dnTCF-1 is not
present in colon cancer (24). Instead its expression has
been replaced by FL-TCF1. The TCF7 locus (which
encodes TCF-1 protein) is very similar to the LEF1
locus in that a P1 promoter produces FL-TCF-1 mRNA
and an intronic, alternative P2 promoter produces
dnTCF-1 mRNA. Thus, the observed switch in TCF-1
expression during colon carcinogenesis is most likely due
to a switch in promoter activities. A fundamental question
to address then is how it is that expression of all the
dominant negative forms of LEF/TCFs are suppressed
in colon cancer. Our work to deﬁne the mechanisms that
govern aberrant LEF-1 expression is the ﬁrst approach to
answer this question. In the current study, we show that
LEF1 P2 is silent in colon cancer cells because the
upstream repressor element (165bp) and the core
promoter factor YY1 cooperate to repress P2
transcription.
YY1 is a multifunctional protein that binds to a large
number of cellular and viral genes (7,8). The YY1-binding
site at+25 in LEF1 P2, (50-CAGATGGAG-30), is a strong
match to the known YY1 consensus binding site
[C(ga)G(t)C(ta)CATNT(a)T(gc)]. Using in vitro and
in vivo methods, we conﬁrmed that YY1 binds to the
+25 region. In fact, there are other general characteristics
of YY1 binding that apply to the site in LEF1 P2. YY1
motifs are overrepresented in core promoters and genome
wide ChIP–chip studies in HeLa cells reveal that RNA
polymeraseII promoters are highly enriched for
YY1-binding sites (25). More than 3% of the RNA poly-
merase II promoters had detectable YY1 motifs (756
genes) and many of these motifs occurred  30nt down-
stream of the transcription start site in a short 50 untrans-
lated region (50 UTR) (25). These motifs often overlapped
the translation start codon of the open reading frame.
These characteristics are similar to the YY1 element in
LEF1 P2, which has the core YY1 site at +25 within a
short P2 50 UTR. Since these features appear to be shared
among hundreds of RNA Polymerase II promoters, the
transcription regulatory principles that we uncover
for LEF1 P2 may also apply to a larger set of
YY1-connected promoters.
Two functional assays were performed to learn about
the mechanism of YY1 in P2 repression. A knockdown
experiment that depleted endogenous YY1 protein
resulted in partial activated expression of the integrated
luciferase reporter genes in a dose dependent manner, but
only if the upstream repressor was present (Figure 5).
Thus, continuous binding of YY1 to the +25 element is
required for P2 repression of the integrated reporters.
Also, placing the repressor element upstream of LEF1
P1, and introducing a single YY1-binding site in an analo-
gous position with only a 3-nt change conferred repression
(Figure 6). Because wild-type LEF1 P1 is not normally
responsive to the repressor, it was the introduction of
the YY1-binding site that enabled communication
between the repressor and the core promoter for transcrip-
tional silencing.
We also analyzed endogenous LEF1 expression upon
YY1 knockdown using northern and western blot
assays. We did not detect any change in the expression
of FL-LEF1 or dnLEF-1 mRNA or protein over the
course of the 72h experiment (data not shown). Thus,
even though knockdown of YY1 is suﬃcient to activate
an integrated P2 luciferase reporter gene, it is not suﬃcient
to activate endogenous P2, at least in this time frame.
Either loss of YY1 is not suﬃcient and another factor
must be eliminated for re-activation of P2, or YY1 is no
longer necessary for the maintenance of a silent LEF1 P2
promoter. It is also possible that our partial YY1
knockdown did not reduce protein levels low enough for
relief of repression. A longer time-course of knockdown
was not possible as the cells could not tolerate YY1 re-
duction and began to die at 72h.
We also performed ChIP assay to detect repressive
histone marks H3K9me3 and H3K27me3 in the presence
and absence of YY1. Interestingly, we observed high
enrichment of H3K9 methylation on the integrated
P2 when YY1 was present and dramatic reductions
when YY1 was eliminated (Figure 5C). This result was
consistent with our YY1 knockdown P2 luciferase assay
when we detected partial reactivation of integrated P2
plasmid. Endogenous P2 was methylated, although not
as high as integrated P2, but methylation was not
reduced as a result of YY1 knockdown. This may
explain why we do not observe reactivation of the en-
dogenous P2 locus.
How is YY1 involved in P2 repression? YY1 is an ex-
tremely versatile transcription factor. YY1 binds and
bends DNA and it can bind to RNA (26). YY1 can
recruit regulatory proteins for either transcription activa-
tion or repression depending on the context [for review see
(7,8)]. In the case of repression, YY1 acts as a Polycomb
group (PcG) protein and recruits chromatin modifying
co-repressors such as histone deacetylases and histone
methyl transferases (7,11,27–29). In some cases of repres-
sion, YY1 action is required transiently at the beginning of
the silencing process and is not necessary at later stages
when a silent epigenetic signature of histone methylation
and de-acetylation has been established (30,31). Perhaps
the inability to reactivate the endogenous LEF1 P2 locus is
due to stable, YY1-independent-maintenance of silencing.
If so, then our stable cell lines with the integrated
luciferase plasmids report on early events of repression
where YY1 is involved whereas endogenous P2 represents
the permanent silent state maintained by epigenetic marks
rather than YY1. This second layer of epigenetic repres-
sion maintains strong silencing such that reduction of
YY1 no longer has an eﬀect. A similar ﬁnding was
recently reported for human HOXD11 and 12 genes,
which are repressed by YY1 and Polycomb group
related proteins recruited to a distal repressor. YY1 and
co-factors are involved in the initial repression of
HOXD11, HOXD12 during diﬀerentiation of human
6386 Nucleic Acids Research, 2010,Vol.38, No. 19mesenchymal stem cells into either osteoblasts or adipo-
cytes (31). Interestingly, YY1 was no longer associated
with the repressor region in the diﬀerentiated osteoblasts,
even though repression was still maintained.
Based on what is known about YY1-mediated repres-
sion and the data presented here, we propose a model for
the role of YY1 in LEF1 P2 repression. First, YY1
binding to P2 is necessary to recruit the upstream repres-
sor to act upon the core promoter. We cannot say that
YY1 is suﬃcient, because even though a single, introduced
YY1 site is enough to make P1 repressor-susceptible,
other common components of the P1 and P2 core pro-
moters, or accessory components of the RNA polymerase
II pre-initiation complex may also be necessary. Also,
YY1 is a DNA-bending protein and may use the
bending feature to facilitate interactions of proteins on
either side of its binding site to eﬃciently recruit the
upstream repressor complex (32). Second, YY1 is a PcG
protein and we therefore propose that repressor recruit-
ment results in the association of chromatin modifying
PcG complexes and changes in chromatin acetylation
and methylation. Indeed, while LEF1 P1 chromatin is
very highly acetylated in colon cancer nuclei, these levels
change signiﬁcantly over the next 5000bp where a sharp
drop in acetylation begins at the upstream repressor
region and continues through LEF1 P2 (4). Alteration of
the local chromatin structure could negatively aﬀect the
ability of TCF–b-catenin complexes to recognize WREs or
the ability of core promoter factors to activate the general
transcriptional machinery.
The predicted outcome of YY1 action on LEF1 is
silencing of dnLEF-1 expression, allowing FL-LEF-1
and other FL-TCFs to act unopposed in their regulation
of Wnt target genes. As such, YY1 appears to positively
aﬀect Wnt signaling. While our study is the ﬁrst to link the
actions of transcription factor YY1 to Wnt signaling, YY1
expression and activity have been previously associated
with tumorigenesis in a wide range of human cancers
including human colorectal cancer where it is
overexpressed (7,33). Indeed, we ﬁnd that YY1
knockdown is lethal to colon cancer cells. It will be im-
portant to determine just how tightly linked oncogenic
Wnt signaling and YY1 actions are in colon cancer and
whether this applies to other tumor types. Additionally,
since the YY1 motif is overrepresented in human pro-
moters, it is possible that a subset of these are subject to
repressor actions similar to LEF1 P2. It is therefore im-
portant to deﬁne the repressor element and the complexes
and protein(s) that associate with it for YY1-linked
regulation.
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